Mirae Asset Global Investments Co. Ltd. Acquires 1,748 Shares of Zymeworks Inc. (NYSE:ZYME)

Mirae Asset Global Investments Co. Ltd. lifted its holdings in Zymeworks Inc. (NYSE:ZYME) by 6.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,958 shares of the company’s stock after purchasing an additional 1,748 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Zymeworks were worth $290,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Acadian Asset Management LLC raised its position in Zymeworks by 742.4% during the third quarter. Acadian Asset Management LLC now owns 825,988 shares of the company’s stock worth $5,233,000 after acquiring an additional 727,934 shares in the last quarter. Jupiter Asset Management Ltd. raised its position in Zymeworks by 913.0% during the third quarter. Jupiter Asset Management Ltd. now owns 474,724 shares of the company’s stock worth $3,010,000 after acquiring an additional 427,860 shares in the last quarter. AQR Capital Management LLC raised its position in Zymeworks by 70.3% during the third quarter. AQR Capital Management LLC now owns 799,679 shares of the company’s stock worth $5,070,000 after acquiring an additional 330,213 shares in the last quarter. Rubric Capital Management LP raised its position in Zymeworks by 12.5% during the third quarter. Rubric Capital Management LP now owns 2,651,394 shares of the company’s stock worth $16,810,000 after acquiring an additional 293,817 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in Zymeworks by 359.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 189,444 shares of the company’s stock worth $1,201,000 after acquiring an additional 148,212 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Zymeworks Trading Up 1.8 %

NYSE ZYME opened at $8.26 on Friday. The firm’s fifty day moving average price is $10.44 and its two-hundred day moving average price is $9.62. Zymeworks Inc. has a 1 year low of $6.01 and a 1 year high of $13.14. The firm has a market capitalization of $582.91 million, a P/E ratio of -4.75 and a beta of 1.14.

Zymeworks (NYSE:ZYME) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.19. Zymeworks had a negative net margin of 156.12% and a negative return on equity of 26.20%. The firm had revenue of $16.93 million for the quarter, compared to analyst estimates of $18.32 million. On average, research analysts anticipate that Zymeworks Inc. will post -1.04 EPS for the current fiscal year.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.